Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

被引：44

作者：

van de Kerkhove, MP

Di Florio, E

Scuderi, V

Mancini, A

Belli, A

Bracco, A

Scala, D

Scala, S

Zeuli, L

Di Nicuolo, G

Amoroso, P

Calise, F

Chamuleau, RAFM

机构：

[1] Acad Med Ctr, Surg Lab, NL-1105 AZ Amsterdam, Netherlands

[2] Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands

[3] Acad Med Ctr, Dept Hepatol, NL-1105 AZ Amsterdam, Netherlands

[4] D Cotugno Hosp, Virol Lab, Naples, Italy

[5] D Cotugno Hosp, Div Infect Dis 11, Naples, Italy

来源：

CELL TRANSPLANTATION | 2003年 / 12卷 / 06期

关键词：

acute liver failure; bioartificial liver; hepatocyte; transplantation; human; porcine; clinical trial;

D O I：

10.3727/000000003108747163

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 X 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 It by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

引用

页码：563 / 568

页数：6

共 24 条

[21]

*UN NETW ORG SHAR, 2002, LIV TRANSPL DAT

[22] Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice [J].